Pharmacotherapy Analysis for Hospitalized Patients with COVID-19 (Prescriptions, Costs, and Outcomes)

Chowdhury R, Heng K, Shawon MSR, Goh G, Okonofua D, Ochoa-Rosales C, et al. Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries. Eur J Epidemiol. 2020;

(5):389-99. doi: 10.1007/s10654-020-00649-w. [PubMed: 32430840].

WHO. Coronavirus disease (COVID-19): weekly epidemiological. World Health Organization; 2020.

Pan X, Dong L, Yang L, Chen D, Peng C. Potential drugs

for the treatment of the novel coronavirus pneumonia

(COVID-19) in China. Virus Res. 2020;286:198057. doi: 10.1016/j.virusres.2020.198057. [PubMed: 32531236].

Cost KT, Crosbie J, Anagnostou E, Birken CS, Charach A, Monga S, et al. Mostly worse, occasionally better: impact of COVID-19 pandemic on the mental health of Canadian children and adolescents. Eur Child Adolesc Psychiatry. 2022;31(4):671-84. doi: 10.1007/s00787-021-01744-3. [PubMed: 33638005].

McKee M, Stuckler D. If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future. Nat Med. 2020;26(5):640-2. doi: 10.1038/s41591-020-0863-y. [PubMed: 32273610].

Congly SE, Varughese RA, Brown CE, Clement FM, Saxinger L. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis. Sci Rep. 2021;11(1):1-7. doi: 10.1038/s41598-021-97259-7. [PubMed: 34493774].

Yamin M. Counting the cost of COVID-19. Int J Inf Technol. 2020;12(2):311-7. doi: 10.1007/s41870-020-00466-0. [PubMed: 32412538].

Carta A, Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients-a hypothetical study. BMC Health Serv Res. 2021;21(1):1-12. doi: 10.1186/s12913-021-06998-w. [PubMed: 34537034].

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-25. doi: 10.1056/NEJMoa2016638. [PubMed: 32492293].

Docherty A, Harrison E, Green C, Hardwick H, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;

:m1985. doi: 10.1136/bmj.m1985. [PubMed: 32444460].

WHO. Case-based payment systems for hospital funding in Asia an investigation of current status and future directions: an investigation of current status and future directions. OECD Publishing; 2015.

Yigezu A, Zewdie SA, Mirkuzie AH, Abera A, Hailu A, Agachew M, et al. Cost-analysis of COVID-19 sample collection, diagnosis, and contact tracing in low resource setting: The case of Addis Ababa, Ethiopia. PloS One. 2022;17(6):e0269458. doi: 10.1371/journal.pone.0269458. [PubMed: 35679290].

Thant PW, Htet KT, Win WY, Htwe YM, Htoo TS. Cost estimates of COVID-19 clinical management in Myanmar. BMC Health Serv Res. 2021;21(1):1-10. doi: 10.1186/s12913-021-07394-0. [PubMed: 34961536].

Memirie ST, Yigezu A, Zewdie SA, Mirkuzie AH, Bolongaita S, Verguet S. Hospitalization costs for COVID-19 in Ethiopia: Empirical data and analysis from Addis Ababa’s largest dedicated treatment center. PloS One. 2022;17(1):e0260930. doi: 10.1371/journal.pone.0260930. [PubMed: 35061674].

Hayati H. Comparison of the Unit Cost of Diagnostic Imaging Services Before and During the COVID-19 Pandemic Using the Activity-Based Costing (ABC) Method. Iran J Radiol. 2022;19(3):e123781.

Hayati H, Kebriaeezadeh A, Ehsani MA, Nikfar S, Sari AA, Mehrvar A, et al. Cost-Utility of protocols of BFM-ALL and UK-ALL for treatment of children with acute lymphoblastic leukemia in Iran. Iran J Public Health. 2018;47(3):407-12. [PubMed: 29845029].

Jin H, Wang H, Li X, Zheng W, Ye S, Zhang S, et al. Economic burden of COVID-19, China, January–March, 2020: a cost-of-illness study. Bull World Health Organ. 2021;99(2):112-24. doi: 10.2471/BLT.20.267112. [PubMed: 33551505].

Hayati H, Kebriaeezadeh A, Ehsani M-A, Nikfar S. Cost-Analysis of Treatment of Childhood Acute Lymphoblastic Leukemia Based on UKALL Protocol. Iran J Pediatr. 2018;28(6):e7985. doi: 10.5812/ijp.7985.

Rahati M, Fakharian E, Yousefianarani A, Omidvar A, Nazemi-bidgoli Z. Treatment Cost of COVID-19 in Hospitals

affiliated to Kashan University of Medical Sciences: Time-Driven Activity-Based Costing. MSHSJ. 2021;5(4):1-13. doi: 10.18502/mshsj.v5i4.5808.

Sinha P. Tocilizumab cost effective in reducing COVID-19-related deaths. PharmacoEcon Outcomes News. 2021;879(1):28-9. doi: 10.1007/s40274-021-7751-7. [PubMed: 34075294].

Jiang Y. Remdesivir cost effective for severe COVID-19 in China. PharmacoEcon Outcomes News. 2021;877(1):17-1. doi: 10.1007/s40274-021-7666-3. [PubMed: 33948076].

Rae M, Claxton G, Kurani N, McDermott D, Cox C. Potential costs of coronavirus treatment for people with employer coverage. Peterson Kaiser FF. 2020;13:1-13.

Yaghoubi M, Salimi M, Meskarpour-Amiri M, Hosseini_shokouh SM. COVID-19-related absenteeism and presenteeism among healthcare workers. Iran Red Crescent Med J. 2022;

(10):e1785. doi: 10.32592/ircmj.2022.24.10.1785.

留言 (0)

沒有登入
gif